Is PYXS or TIL more profitable?

Instil Bio's return on equity of -26.78% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -215.23% -112.19% Instil Bio N/A -26.78% -14.89%

Which has preferable earnings & valuation, ADAG or TIL?

Adagene has higher revenue and earnings than Instil Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 23.77 -$17.61M N/A N/A Instil Bio N/A N/A -$71.37M -$4.47 N/A

Is ADAG or TIL more profitable?

Adagene's return on equity of 0.00% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Instil Bio N/A -26.78% -14.89%

Which has better valuation & earnings, NKTX or TIL?

Instil Bio is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.57 N/A Instil Bio N/A N/A -$71.37M -$4.47 N/A

Is NKTX or TIL more profitable?

Instil Bio's return on equity of -26.78% beat Nkarta's return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -39.64% -30.45% Instil Bio N/A -26.78% -14.89%

Is CUE or TIL more profitable?

Instil Bio has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Instil Bio's return on equity of -26.78% beat Cue Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Cue Biopharma -435.83% -620.06% -291.15% Instil Bio N/A -26.78% -14.89%

Which has stronger earnings & valuation, TIL or IPHA?

Innate Pharma has higher revenue and earnings than Instil Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$4.47 N/A Innate Pharma $10.19M 17.76 -$55.64M N/A N/A

Is TIL or IPHA more profitable?

Innate Pharma's return on equity of 0.00% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -26.78% -14.89% Innate Pharma N/A N/A N/A

Instil Bio (TIL) Competitors

$6.74 +0.18 (+2.74%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.62 -0.12 (-1.78%)

As of 10/9/2026 04:06 PM Eastern

Compare

TIL vs. PYXS, ADAG, NKTX, CUE, and IPHA

Should you buy Instil Bio stock or one of its competitors? Instil Bio's main competitors and comparable companies include Pyxis Oncology (PYXS), Adagene (ADAG), Nkarta (NKTX), Cue Biopharma (CUE), and Innate Pharma (IPHA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Instil Bio compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Pyxis Oncology has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 47.0% of Instil Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Instil Bio has lower revenue, but higher earnings than Pyxis Oncology. Instil Bio is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$11.04M	15.34	-$79.62M	-$1.41	N/A
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A

Instil Bio's return on equity of -26.78% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Instil Bio	N/A	-26.78%	-14.89%

Pyxis Oncology presently has a consensus price target of $8.75, suggesting a potential upside of 331.03%. Instil Bio has a consensus price target of $7.00, suggesting a potential upside of 3.86%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Pyxis Oncology is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Pyxis Oncology had 4 more articles in the media than Instil Bio. MarketBeat recorded 5 mentions for Pyxis Oncology and 1 mentions for Instil Bio. Pyxis Oncology's average media sentiment score of 0.82 beat Instil Bio's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Pyxis Oncology	Positive
Instil Bio	Neutral

Summary

Pyxis Oncology beats Instil Bio on 8 of the 14 factors compared between the two stocks.

How does Instil Bio compare to Adagene?

Adagene (NASDAQ:ADAG) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Adagene has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market.

Adagene has higher revenue and earnings than Instil Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	23.77	-$17.61M	N/A	N/A
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A

In the previous week, Adagene had 3 more articles in the media than Instil Bio. MarketBeat recorded 4 mentions for Adagene and 1 mentions for Instil Bio. Adagene's average media sentiment score of 0.80 beat Instil Bio's score of 0.00 indicating that Adagene is being referred to more favorably in the media.

Company	Overall Sentiment
Adagene	Positive
Instil Bio	Neutral

Adagene's return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Instil Bio	N/A	-26.78%	-14.89%

9.5% of Adagene shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Adagene presently has a consensus target price of $8.67, suggesting a potential upside of 214.01%. Instil Bio has a consensus target price of $7.00, suggesting a potential upside of 3.86%. Given Adagene's stronger consensus rating and higher possible upside, research analysts clearly believe Adagene is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Adagene beats Instil Bio on 10 of the 13 factors compared between the two stocks.

How does Instil Bio compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Nkarta and Nkarta both had 1 articles in the media. Nkarta's average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company	Overall Sentiment
Nkarta	Neutral
Instil Bio	Neutral

Instil Bio's return on equity of -26.78% beat Nkarta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-39.64%	-30.45%
Instil Bio	N/A	-26.78%	-14.89%

Nkarta presently has a consensus price target of $11.20, suggesting a potential upside of 397.78%. Instil Bio has a consensus price target of $7.00, suggesting a potential upside of 3.86%. Given Nkarta's stronger consensus rating and higher possible upside, research analysts clearly believe Nkarta is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 9.8% of Nkarta shares are owned by insiders. Comparatively, 47.0% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Instil Bio is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A

Nkarta has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market.

Summary

Nkarta beats Instil Bio on 7 of the 12 factors compared between the two stocks.

How does Instil Bio compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Cue Biopharma has a beta of 2.62, suggesting that its share price is 162% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, suggesting that its share price is 94% more volatile than the broader market.

Instil Bio has a net margin of 0.00% compared to Cue Biopharma's net margin of -435.83%. Instil Bio's return on equity of -26.78% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-435.83%	-620.06%	-291.15%
Instil Bio	N/A	-26.78%	-14.89%

Cue Biopharma presently has a consensus target price of $83.00, indicating a potential upside of 200.07%. Instil Bio has a consensus target price of $7.00, indicating a potential upside of 3.86%. Given Cue Biopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Cue Biopharma is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Cue Biopharma has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	7.31	-$26.60M	-$27.02	N/A
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 47.0% of Instil Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cue Biopharma had 2 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for Cue Biopharma and 1 mentions for Instil Bio. Cue Biopharma's average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company	Overall Sentiment
Cue Biopharma	Neutral
Instil Bio	Neutral

Summary

Cue Biopharma beats Instil Bio on 8 of the 14 factors compared between the two stocks.

How does Instil Bio compare to Innate Pharma?

Instil Bio (NASDAQ:TIL) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Innate Pharma's average media sentiment score of 0.85 beat Instil Bio's score of 0.00 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Instil Bio	Neutral
Innate Pharma	Positive

Innate Pharma has higher revenue and earnings than Instil Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A
Innate Pharma	$10.19M	17.76	-$55.64M	N/A	N/A

Instil Bio presently has a consensus price target of $7.00, indicating a potential upside of 3.86%. Innate Pharma has a consensus price target of $6.67, indicating a potential upside of 311.52%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Innate Pharma's return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-26.78%	-14.89%
Innate Pharma	N/A	N/A	N/A

Instil Bio has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Summary

Innate Pharma beats Instil Bio on 8 of the 11 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TIL vs. The Competition

Export

Metric	Instil Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$44.49M	$3.85B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-1.51	13.62	275.30	26.16
Price / Sales	N/A	1,234.33	635.97	107.53
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	0.40	17.17	11.22	6.33
Net Income	-$71.37M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-6.65%	-1.34%	-0.89%	-1.40%
1 Month Performance	-8.42%	-8.45%	-4.42%	-3.47%
1 Year Performance	-64.95%	14.02%	7.03%	1.18%

Instil Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TIL Instil Bio	1.2582 of 5 stars	$6.74 +2.7%	$7.00 +3.9%	-67.5%	$44.49M	N/A	N/A	410	Positive News
PYXS Pyxis Oncology	2.6105 of 5 stars	$2.02 -9.8%	$8.75 +333.2%	-47.0%	$186.83M	$11.04M	N/A	56
ADAG Adagene	4.0437 of 5 stars	$2.93 +4.6%	$8.67 +195.8%	+41.5%	$184.94M	$7.67M	N/A	128	Positive News
NKTX Nkarta	2.9967 of 5 stars	$2.31 -8.7%	$11.20 +384.8%	-4.7%	$181.21M	N/A	N/A	106
CUE Cue Biopharma	2.5341 of 5 stars	$23.14 -5.0%	$83.00 +258.7%	-96.7%	$176.96M	$27.47M	N/A	29	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TIL) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Instil Bio (TIL) Competitors

TIL vs. PYXS, ADAG, NKTX, CUE, and IPHA

How does Instil Bio compare to Pyxis Oncology?

Summary

How does Instil Bio compare to Adagene?

Summary

How does Instil Bio compare to Nkarta?

Summary

How does Instil Bio compare to Cue Biopharma?

Summary

How does Instil Bio compare to Innate Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Instil Bio (TIL) Competitors

TIL vs. PYXS, ADAG, NKTX, CUE, and IPHA

How does Instil Bio compare to Pyxis Oncology?

Which has more volatility and risk, PYXS or TIL?

Do insiders and institutionals hold more shares of PYXS or TIL?

Which has better valuation & earnings, PYXS or TIL?

Is PYXS or TIL more profitable?

Do analysts prefer PYXS or TIL?

Does the media favor PYXS or TIL?

Summary

How does Instil Bio compare to Adagene?

Which has more volatility & risk, ADAG or TIL?

Which has preferable earnings & valuation, ADAG or TIL?

Does the media favor ADAG or TIL?

Is ADAG or TIL more profitable?

Do insiders and institutionals believe in ADAG or TIL?

Do analysts recommend ADAG or TIL?

Summary

How does Instil Bio compare to Nkarta?

Does the media prefer NKTX or TIL?

Is NKTX or TIL more profitable?

Do analysts rate NKTX or TIL?

Do institutionals and insiders hold more shares of NKTX or TIL?

Which has better valuation & earnings, NKTX or TIL?

Which has more volatility & risk, NKTX or TIL?

Summary

How does Instil Bio compare to Cue Biopharma?

Which has more risk & volatility, CUE or TIL?

Is CUE or TIL more profitable?

Do analysts rate CUE or TIL?

Which has stronger earnings and valuation, CUE or TIL?

Do institutionals and insiders have more ownership in CUE or TIL?

Does the media favor CUE or TIL?

Summary

How does Instil Bio compare to Innate Pharma?

Do insiders and institutionals have more ownership in TIL or IPHA?

Does the media refer more to TIL or IPHA?

Which has stronger earnings & valuation, TIL or IPHA?

Do analysts prefer TIL or IPHA?

Is TIL or IPHA more profitable?

Which has more risk and volatility, TIL or IPHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools